ArticleScientific reports2025
Extract of Bombycis Feces suppressed 3T3-L1 adipogenesis resulting in the regulation of fatty acid-dependent energy consumption.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In Oriental medicine, silkworms and their derivatives have been used for anti-inflammatory and diabetic purposes. Bombycis Feces exhibit anti-atopic effects and anti-proliferative activity; however, the role of BF extract (BFE) in adipogenesis and obesity and management remains underexplored. This study examined the effects of BFE on amino acid oxidation during adipocyte differentiation. An adipogenesis model was established using 3T3-L1 cells. Intracellular lipid accumulation was assessed via Oil Red O staining, while cytotoxicity was evaluated using a cell viability assay. The effects of BFE on gene and protein expression, lipolysis, real-time oxygen consumption rate, and substrate oxidation during adipocyte differentiation were analyzed. The involvement of the branched-chain amino acid (BCAA) catabolic pathway and leptin gene expression was also evaluated. BFE treatment significantly downregulated the expression level of key adipogenic transcription factors, including PPARγ and C/EBPα, as well as aP2 gene expression. Lipid accumulation was significantly reduced, accompanied by increased expression of Sirt1 and Sirt6, but not Sirt3, and a concurrent reduction in Parp1 expression. In addition to adipogenesis, the oxygen consumption rate and extracellular acidification rate were downregulated by BFE treatment in adipocytes. Conversely, BFE enhanced amino acid-dependent oxidation during adipogenesis. These findings suggest that BFE supports energy production via BCAA catabolism rather than fatty acid or glucose oxidation. BFE inhibits adipogenesis by modulating the expression of Sirt1, Sirt6, and Parp1, reducing lipid metabolism, and enhancing BCAA catabolism in 3T3-L1 cells. These results highlight BFE's potential as a therapeutic agent for obesity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.